Changes in Hong Kong stocks | McPharmaceutical-B (02335) soared more than 115%, adopted an H share incentive plan and sought to buy back no more than 10% of H shares

The Zhitong Finance App learned that McPharmaceutical-B (02335) soared more than 115% in early trading. As of press release, it rose 111.21% to HK$30.9, with a turnover of HK$33.2524 million.

According to the news, McPharma announced that the board of directors proposed the adoption of the H share incentive plan, which is valid for ten years from the date of adoption, and will seek shareholders' approval at an extraordinary shareholders' meeting. At the same time, the board of directors is seeking to grant a general share repurchase mandate of no more than 10% of the total number of H shares issued.

According to public information, McPharmaceuticals focuses on the fields of cardiovascular, renal and metabolic diseases, and has built a pipeline matrix composed of one core product and six key candidate products. Seven pipelines have entered clinical trials, and six have achieved double reporting between China and the US. It is one of the enterprises with the largest number of clinical-stage pipelines and leading technology in the field of innovative peptide drugs in China.